Cim, LLC Corcept Therapeutics Inc Transaction History

Cim, LLC

$676 Million
Q2 2024

A detailed history of Cim, LLC transactions in Corcept Therapeutics Inc stock. As of the latest transaction made, Cim, LLC holds 15,909 shares of CORT stock, worth $606,769. This represents 0.08% of its overall portfolio holdings.

Number of Shares

15,909

Previous 15,779 0.82%

Holding current value

$606,769

Previous $397,000 29.97%

% of portfolio

0.08%

Previous 0.06%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Sep 06, 2024	BUY	$22.21 - $34.48 $2,887 - $4,482	130 Added 0.82%	15,909 $516,000
Q1 2024 May 20, 2024	BUY	$21.1 - $27.46 $2,721 - $3,542	129 Added 0.82%	15,779 $397,000
Q4 2023 Feb 23, 2024	BUY	$24.82 - $32.88 $39,786 - $52,706	1,603 Added 11.41%	15,650 $508,000
Q3 2023 May 17, 2024	BUY	$21.97 - $33.8 $4,108 - $6,320	187 Added 1.33%	14,239 $388,000
Q2 2023 May 17, 2024	SELL	$21.44 - $25.15 $34,261 - $40,189	-1,598 Reduced 10.21%	14,052 $312,000
Q1 2023 May 17, 2024	SELL	$19.2 - $24.47 $37,401 - $47,667	-1,948 Reduced 12.45%	13,702 $296,000
Q4 2022 Feb 10, 2023	SELL	$19.95 - $29.96 $6,643 - $9,976	-333 Reduced 2.32%	14,047 $285,000
Q3 2022 Nov 02, 2022	BUY	$24.7 - $29.12 $24,601 - $29,003	996 Added 7.44%	14,380 $431,000
Q2 2022 Jul 11, 2022	BUY	$17.33 - $25.3 $63,739 - $93,053	3,678 Added 37.89%	13,384 $370,000
Q1 2022 Apr 12, 2022	BUY	$16.53 - $25.21 $160,440 - $244,688	9,706 New	9,706 $234,000
Q4 2018 Jan 29, 2019	SELL	$11.29 - $17.19 $123,885 - $188,625	-10,973 Closed	0 $0
Q3 2018 Oct 29, 2018	BUY	$12.27 - $15.65 $134,638 - $171,727	10,973 New	10,973 $154,000

Others Institutions Holding CORT

# of Institutions

311

Shares Held

88.3M

Call Options Held

1.07M

Put Options Held

973K

View Full List

About CORCEPT THERAPEUTICS INC

Ticker CORT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,105,000
Market Cap $4.08B
Description
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients ...

More about CORT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cim, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cim, LLC with notifications on news.

Account